Revascularisation of complex patients in stable coronary artery disease
A predictor for 10-year mortality and clinical events in patients with chronic coronary total occlusion lesion
K Kim
10 years of clinical follow-up, MACCE occurs 6%, all-cause death in 18.5%, cardiac death in 9.9%, myocardial infarction (MI) 7.7%, revascularization in 30.7%, and stroke in 6.3% of patients
A prior myocardial infarction, reduced LV ejection fraction, chronic kidney disease, and multi-vessel disease were associated with an increased risk of MACCE
While the use of statins and aspirin reduced the risk of MACCE
PCI for CTO lesions did not reduce the incidence of MACCE or all-cause death
Partnering with patients through digital health
Quality of life after pulmonary veins isolation: outcomes from a digital follow-up program
R Teixeira
No significant differences were seen according to baseline age and AF type
During follow-up, AF recurred in 14.5% of patients, < 7% of patients had at least one emergency department visit and no deaths were reported
Among patients with symptomatic AF, ablation led to significant improvements in QoL at 12 months
Males in whom antiarrhythmic drugs were discontinued reported higher improvement in QoL
Hypertension phenotypes and arterial stiffness
Arterial stiffness assessment in patients with resistant hypertension using pulse wave analysis
A Akhmimi
The office and central BP readings were elevated in the resistant hypertension (RH) group compared to essential hypertension (CH) and normotensive (NC) (P<0.001)
Aortic pulse pressure, MAP, and aortic augmentation pressure were significantly increased in patients with RH compared to other groups (P<0.001)
Elevated AIx (Aortic augmentation index) was significantly and independently associated with the presence of RH
Diabetes and stable coronary artery disease
Real-life use of novel glucose-lowering agents after acute myocardial infarction and stable coronary artery disease in patients with diabetes - experience from national use in the SWEDEHEART registry
V Ritsinger
The use of novel glucose-lowering agents increased rapidly from 7% to 47% from 2016 year
Use of SGLT2i increased from 4% to 38% and GLP-1 RA from 4% to 15%
The cumulative event rate in all-cause death within 1 year occurred in 7% of patients with SGLT2i and/or GLP-1 RA compared to 4.5% in patients without new cardioprotective agents
Increased awareness is needed to use effective cardioprotective treatment also in a high-risk population
Effect of initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy on ambulatory blood pressure indices
J Nolde
At 12 weeks, mean 24-h ambulatory systolic and diastolic BP were 7 and 5.3 mmHg lower in the quadpill versus monotherapy group (p<0.001 for both)
The reduction in systolic and diastolic ambulatory BP variability was more pronounced in the quadpill group at 12 weeks
The rate of BP control at 12 weeks was higher in the quadpill group (p<0.001). These effects were maintained at 52 weeks.
A quadruple quarter-dose combination compared to monotherapy resulted in greater ambulatory BP lowering across the entire 24-hour period with higher ambulatory BP control rates at both 12 and 52 weeks
Comparison of de-escalation of DAPT intensity or duration in East Asian and Western patients with ACS undergoing PCI: A systematic review and meta-analysis
DA Gorog
Reduced DAPT intensity attenuated major bleeding (p=0.009) without impacting net adverse cardiovascular events (NACE) or major adverse cardiovascular events (MACE)
In East Asians (EA), it reduced major bleeding (p=0.02) without affecting NACE or MACE
Individualisation of DAPT strategy may be preferable to personalise care based on both ethnicity and prevailing risks
Standard DAPT favours patients at high ischaemic risk, while shorter or less intense DAPT may benefit those at high bleeding risk
MINOCA in a young patient with antiphospholipid syndrome
M Bernardo
Antiphospholipid syndrome can cause venous or arterial thrombosis and should be considered in young patients presenting with a myocardial infarction, as it might be the initial sign of the syndrome.
In the presenting case of MINOCA, CMR was essential for diagnosis
An ICD is recommended in patients with symptomatic HF and LVEF ≤35% despite ≥3 months of OMT
Short and optimal duration of dual-antiplatelet therapy study after everolimus-eluting cobalt-chromium stent-3
STOPDAPT-3: An Aspirin-Free antithrombotic strategy for percutaneous coronary intervention
Natsuaki M
Aspirin-free strategy using low-dose Prasugrel compared with DAPT failed to attest superiority for major bleeding within 1 month after PCI
Aspirin used for limited period after PCI, DAPT exerted protective effect on coronary lesions regardless of the treatment
No-aspirin group compared to DAPT was associated with excess of coronary events
Functional versus Culprit-only revascularization in elderly patients with myocardial infarction and multivessel disease
FIRE trial: Physiology-Guided Complete PCI in Older MI Patients
S Biscaglia
Among patients aged ≥75 years with MI complete revascularization as compared to culprit-only revascularization strategy, reduced
composite of death, MI, stroke, or ID revascularization
Cardiovascular death or MI
The safety endpoint in culprit-only reported 20.4% and for complete 22.5%
MI Trajectory- Subsequent cardiovascular disease trajectories following myocardial infarction
C Nathalie
The study reported that cardiovascular diseases showed 47% mortality compared to lung diseases(20%) and infections (8%)
Heart failure is the strongest predictor of mortality (more than MI)
Important reductions in in-hospital mortality among patients with MI have translated in modest improvements in long-term survival
Heart failure is the common consequence of MI
Heart failure should be the focus for new preventive strategies after MI
